Insider Selling: Scholar Rock (NASDAQ:SRRK) Insider Sells $193,425.21 in Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Jing Marantz sold 4,157 shares of Scholar Rock stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total value of $193,425.21. Following the transaction, the insider directly owned 126,012 shares in the company, valued at $5,863,338.36. The trade was a 3.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Scholar Rock Trading Up 0.6%

Shares of SRRK stock opened at $48.00 on Friday. Scholar Rock Holding Corporation has a 1-year low of $22.71 and a 1-year high of $49.82. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. The stock has a market cap of $4.90 billion, a price-to-earnings ratio of -15.24 and a beta of 0.67. The stock has a 50-day moving average of $45.16 and a 200-day moving average of $38.38.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research note on Thursday, January 22nd. Wolfe Research began coverage on Scholar Rock in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. Citigroup began coverage on Scholar Rock in a research note on Friday, January 9th. They issued a “buy” rating and a $55.00 price target on the stock. Finally, JPMorgan Chase & Co. raised their price objective on shares of Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $51.14.

Institutional Trading of Scholar Rock

Hedge funds and other institutional investors have recently bought and sold shares of the business. IFP Advisors Inc grew its holdings in shares of Scholar Rock by 294.1% during the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after buying an additional 450 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Scholar Rock in the 4th quarter valued at about $30,000. Summit Securities Group LLC acquired a new position in Scholar Rock during the 4th quarter valued at about $31,000. Ramirez Asset Management Inc. acquired a new position in Scholar Rock during the 3rd quarter valued at about $37,000. Finally, EverSource Wealth Advisors LLC increased its holdings in Scholar Rock by 151.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after purchasing an additional 525 shares in the last quarter. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).